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1. Introduction
1.1. Current status of hematopoietic stem cell transplantation in patients with refractory or
relapse hodgkin lymphoma
Although the high response rates, approximately 10% of patients with early-stage Hodgkin
Lymphoma (HL) and 20% with advanced disease will be refractory to initial treatment or
relapse after a first complete response [1-3]. The strategy for management of relapsed or
refractory disease is to deliver salvage chemotherapy, followed by high-dose chemotherapy
and autologous stem-cell transplantation (AutoSCT) in responding patients [4,5].
2. Autologous stem cell transplantation for Hodgkin lymphoma
2.1. Autologous stem cell transplantation at first-line therapy
The use of autoSCT for HL in first remission was wondered. There are only a few prospective
randomized clinical trials focusing in this issue. Although historically controlled studies are
promising, prospective controlled studies showed different results [6].
The HD01 trial included 163 patients achieving complete remission (CR) or partial remission
(PR) with advanced HL after four cycles of ABVD (ABVD; doxorubicin, bleomycin, vinblastine,
and dacarbazine) or other doxorubicin-containing regimens who had an unfavorable risk
profile (at least two factors: high lactate dehydrogenase level, large mediastinal mass, more
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than one extranodal site of disease, low hematocrit, or inguinal involvement). The patients
were randomly divided into two groups; AutoSCT and four additional cycles of conventional
chemotherapy. There was no significant difference regarding complete remission rates, and
the 5-year failure-free survival, overall survival and relapse-free survival rates between the
groups [7]. Similarly, the recently published 10-year follow-up results could not demonstrate
an advantage of the high dose therapy in terms of failure-free survival, overall survival and
relapse-free survival rates between the groups [8]. The HD01 trial suggested that patients
responding to an anthracycline- based regimen do not benefit from autoSCT at first line
therapy.
In the GOELAMS Group’s (Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du
Sang) randomized phase 2 study, H97-HR trial, the authors tested 2 intensive chemotherapy
regimens in 158 patients with stage IIB - IV HL accompanied by high-risk factors. High-risk
were defined by the presence of >5 involved lymphoid areas, and/or a mediastinal mass ratio
> 0.45, and/or >2 extra lymph node sites affected by the disease. This study examined an early
intensive chemotherapy and ABVD for 4 cycles followed by delayed myeloablative intensifi‐
cation. In one of the arms, patients received 3 courses of combined vindesine, doxorubicin,
carmustine, etoposide, and methylprednisolone (VABEM) followed by low-dose lymph node
irradiation. In the other arm, patients received 4 cycles of ABVD followed by myeloablative
regimen containing carmustine, etoposide, cytarabine, and melphalan and underwent
autoSCT. After the completion of treatment, the CR rates for both of arms were similar. The 5-
year freedom from treatment failure and 5-year overall survival rates also were similar
between the arms. Consequently, the authors recommended that conventional chemotherapy
should remain the reference treatment in advanced and high risk HL [9].
In considering all these results, autoSCT for HL does not take place as a part of first line therapy
even for high-risk patients.
2.2. Autologous stem cell transplantation for relapsed/refractory HL
Because conventional salvage chemotherapy and/or radiotherapy have poor results in first
relapsed or progressive HL, autoSCT was evaluated as a curative approach for patients with
relapsed or progressive disease. There were two prospective randomized clinical trials in the
last twenty years. Firstly the British National Lymphoma Investigation performed a random‐
ized smaller prospective study in 40 patients. The aim of the study was comparison of high-
dose chemotherapy (BEAM = carmustine, etoposide, cytarabine, and melphalan) plus autoSCT
(n=20) with the same drugs at lower doses (mini-BEAM) (n=20) in patients with primary
refractory disease, early relapse, or prior failure of conventional therapy. All patients have
been followed up for at least one year. Although there was no difference in overall survival
(OS), both event-free survival and progression-free survival showed statistical significant
differences in favour of BEAM plus autoSCT (p = 0.025 and p = 0.005, respectively) [10]. This
study suggested that High-dose chemotherapy with autoSCT could provide better disease-
free survival but not overall survival.
The second randomized multicenter trial (HD-R1) was performed by investigators of the
German Hodgkin’s disease Study Group and the Lymphoma Working Party (LWP) of the
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EBMT to determine the benefit of HDCT in relapsed HL. Patients were randomly assigned to
either four cycles of conventional chemotherapy (Dexa-BEAM: dexamethasone and carmus‐
tine, etoposide, cytarabine, and melphalan) or two cycles of Dexa-BEAM followed by autoSCT
(n=73, n=88). After two cycles Dexa-BEAM chemotherapy, only 117 patients with chemosen‐
sitive disease proceeded to further treatment. Median follow-up was 39 months (IQR 3–78).
Freedom from treatment failure at 3 years was significantly better for autoSCT patients (55%)
than for those on Dexa-BEAM (34%; difference –21%, 95% CI –39 87 to –2 13; p=0 019), although
OS was not different [11].
Data  from  randomized  trials  established  autoSCT  as  standard  therapy  in  relapsing  HL
patients responding to salvage therapy [11,12,13]. Moskowitz et al reported retrospective
analysis  of  75  consecutive patients  with primary refractory HD,  who were  treated with
high  dose  chemoradiotherapy  and  autoSCT.  Median  follow-up  was  10  years.  Only
chemosensitivity  to  second-line  chemotherapy  predicted  for  a  better  survival,  thus
responding patients had an event-free survival (EFS), progression-free survival (PFS) and
OS of 60%, 62% and 66%, respectively, versus 19%, 23% and 17% for patients who had a
poor response to second-line chemotherapy (P < 0.001). Patients with disease refractory to
first-line  therapy  but  chemosensitive  to  standard-dose  second-line  therapy  might  have
better  outcome  after  an  autoSCT  [14].  Primary  refractory  patients  or  for  patients  in
chemorefractory relapse, autoSCT has only a small likelihood to induce long-term remis‐
sion.  For  these  patients,  autoSCT  can  be  clinical  option  [13].  Patients  with  progressive
disease after  autoSCT have a poor outcome,  and either allogeneic stem cell  transplanta‐
tion or other investigative approaches are necessary [14,15].
Nodular lymphocyte predominant HL (LPNHL) has to be accepted a complete different entity.
There is almost no information in the literature about the impact of autoSCT in those groups
of patients. Nevertheless, autoSCT can be considered a therapeutic option for LPNHL patients
in advanced stages and relapsing after standard treatment [13].
2.3. High dose conditioning regimens for autologous stem cell transplantation
There is no randomized clinical trial comparing different high dose conditioning regimes
for autoSCT. In retrospective analyses, the superiority of a specific regimen has not been
demonstrated.  Total  body  irradiation  (TBI)-based  regimens  as  high  dose  conditioning
regimens  were  compared  to  chemotherapy  combinations.  There  was  no  difference  in
efficacy  and  toxicity  between  the  regimens  [16,17,18].  German  Hodgkin  Study  Group
evaluated the impact of sequential high-dose therapy to increase the intensity of condition‐
ing  before  autoSCT.  Additional  high-dose  therapy  did  not  improve  the  prognosis  of
patients with relapsed HL compared with the standard BEAM regimen and autoSCT, and
was  associated with  increased toxic  effects  [19].  There  was  no  benefit  of  increasing  the
intensity of conditioning regimen. Most of randomized trials of autoSCT in HL used BEAM
regimen and this  regimen is  regarded,  by most transplant centers,  as the standard high
dose-conditioning regimen [20].
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2.4. Prognostic factors associated with outcome in relapse and refractor Hodgkin lymphoma
before autologous stem cell transplantation
Several trials have identified prognostic factors in patients with RR-HL who have undergone
subsequent salvage chemotherapy and autoSCT. These prognostic factors are summarized in
table-I. Extra nodal disease, B symptoms at relapse and short remission duration after initial
therapy have consistently been demonstrated to be predictors of poor outcome. Chemotherapy
resistance prior to autoSCT is generally associated with poor outcome [21].
The depth of response to salvage chemotherapy before autoSCT is important. Detectable
disease with functional imaging has predictive value for an unfavorable outcome [21, 22].
Jabbour et al suggested that positive functional pretransplant imaging (either gallium or
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography; FDG-PET scan) can be
predictive of poor outcome. The 3-year OS rates for patients with negative functional imaging
were 87% but this was 58% in patients with positive functional imaging [22]. Moskowitz et al
demonstrated that patients with negative functional imaging (either gallium or FDG-PET scan)
had 75% EFS compared to 31% for patients with positive functional imaging [21]. Recently,
Moskowitz et al reported a prospective phase 2 study. They used a risk-adapted approach to
improve PFS after high-dose radio chemotherapy and autoSCT. First salvage chemotherapies
were 2 cycles of ICE (ICE; ifosfamide, carboplatin, etoposide) in a standard or augmented dose,
followed by restaging FDG-PET scan. Patients with a negative scan received a transplant. If
the FDG-PET scan was still positive, patients received again chemotherapy (GVD; gemcita‐
bine, vinorelbine, and liposomal doxorubicin). Patients without evidence of disease progres‐
sion proceeded to high-dose chemotherapy (HDT)/ autoSCT. Patients transplanted with
negative FDG-PET had an EFS of > 80%, versus 28.6% for patients with a positive scan (P <.
001). In that study, FDG-PET–negative status is a major factor in the determination of outcome.
The finding that the outcome for patients receiving GVD and having a FDG-PET–negative
result is indistinguishable from patients with ICE-based therapy induced FDG-PET–negative
response argues that quality of response is an important determinant of outcome. The authors
suggested that the goal of salvage chemotherapy in patients with HL should be a negative
FDG-PET scan before HDT/AutoSCT [23].
3. Allogeneic stem cell transplantation
Although allogeneic stem cell transplantation (alloSCT) historically associated with signifi‐
cantly greater treatment-related mortality (TRM) than autologous stem cell transplantation
(autoSCT), Because of the potential for graft versus lymphoma (GVHL) effects and the
assurance of a tumor-free graft, alloSCT is carrying curative potential especially in patients
with Hodgkin lymphoma (HL) who are younger than other lymphoma patients. Nevertheless,
comparative studies between myeloablative alloSCT and autoSCT in refractory and relapsed
HL patients provided evidence of GVHL effect. The widespread use of alloSCT in HL patients
is still a matter of controversy because of the TRM and was quite limited until the advent of
reduced intensity conditioning (RIC). Nowadays, increasing numbers of studies have been
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Prognostic factors Effects of prognostic factories Reference
B symptoms at relapse,
Extranodal disease at relapse,
Initial remission duration of < 1 year
3-year PFS: 24
No risk factor: 100%,
1 risk factor: 81%,
2 risk factors: 40%
3 risk factors: 0%
>2 prior chemotherapy regimens, Patients who had received >2 chemotherapy regimens had a
poorer DFS
17
Performance status; ECOG: 1-3
>1 chemotherapy regimens failed,
The presence of mediastinal disease
at AutoSCT
These factors significantly associated with FFS,
Patients with >2 failed chemotherapy regimens have an
estimated 4 year FFS of 10%.
25
Systemic symptoms at relapse,
Disseminated pulmonary or bone
marrow disease at relapse,
More than minimal disease at
AutoSCT
4-year FFP:
No risk factor: 85%
>1 risk factors: 41%
18
End-of-treatment to relapse
interval < 12 months
Presence of extranodal disease at
relapse
4-year survival: 26
No risk factor: 93%,
1 risk factor: 59%,
2 risk factors: 43%
Chemotherapy resistance prior to
AutoSCT,
Advanced disease stage at
diagnosis (stage ≥III)
These factors associated with a higher risk of disease
progression after transplantation
27
B symptoms,
Extranodal disease,
Complete remission duration of less
than 1 year
EFS:
0-1 risk factor: 83%
2 risk factors: 27%
3 risk factors: 10%
28
Advanced stage at diagnosis,
Radiotherapy before AutoSCT,
A short first CR,
Detectable disease at AutoSCT
5-year TTF:
No risk factor: 71%±4%
3 or more risk factors: 18%±5%
29
Pre-autoSCT positive functional
imaging (FDG-PET or gallium scan)
In this trial, the only factor that predicted an unfavorable
outcome in the transplanted patients was a pre-HDT/AutoSCT–
positive functional imaging
30
Pre-autoSCT, FDG-PET status Persistent FDG-PET positivity after salvage therapy have a poor
outcome with HDT/ AutoSCT
31
EFS: Event-free survival, FFP: Freedom from progression, FFS: Failure-free survival, PFS: Progression-free survival, TTF: Time
to treatment failure, FDG-PET: Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography, HDT: High-dose
chemotherapy
Table 1. Prognostic factors in relapse and refractory HL
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investigating the role of especially RIC-alloSCT in patients with refractory or relapsed HL,
most of whom have previously received autoSCT. [32]
3.1. Myeloablative conditioning regimens
Myeloablative Conditioning (MAC) alloSCT derives its benefit from both the high-dose
conditioning regimen and the GVHL effect. To determine whether this approach would benefit
patients with advanced HL, proof of concept was reported by Appelbaum et al. in Seattle [33].
Eight patients with disseminated HL resistant to MOPP chemotherapy were treated with high-
dose chemoradiotherapy and marrow transplantation from an HLA-match sibling donor
(MSD). Two patients remain alive in unmaintained complete remission (CR) at 38 and 39
months after transplant. In the other six patients, reasons for failure included relapse of
lymphoma (two patients), or death due to complications of the transplant procedure. They
suggest that some patients with MOPP-resistant HL can obtain prolonged CR following
intensive chemoradiotherapy followed by alloSCT.
In Johns Hopkins Oncology Center, the first prospective study to compare autoSCT with
allogeneic marrow transplantation (alloBMT) was done by Jines RJ. et al. [34]. Patients with
HL who have failed two or more chemotherapy regimens or who have relapsed after an initial
chemotherapy-induced remission of less than 12 months are seldom cured with conventional
salvage therapies. They studied the effect of high-dose cytoreductive therapy followed by
alloBMT in 50 patients with relapsed HL. Twenty-one patients with HLA-matched donors had
alloBMT, one patient received marrow from an identical twin, and 28 patients received
autologous grafts. The authors demonstrated that autoSCT and alloSCT yield similar EFS.
However, they did see a difference in relapse rates between recipients of alloSCT (17%) and
autoSCT recipients with chemosensitive disease (34%), which indicated the possibility of a
GVHL effect [34]. In another study Anderson et al. reported from Seattle, between 1970 and
1991, 127 patients (median age, 29 years) with relapsed or refractory HL received high-dose
chemotherapy with or without irradiation, followed by autoSCT (n=68), alloSCT (n=53), or
syngeneic transplantation (n=6) [35]. The 5-year actuarial probabilities of OS, EFS, relapse, and
nonrelapse mortality (NRM) for the entire group were 21%, 18%, 65%, and 49%, respectively.
HLA-match allogeneic marrow recipients had a statistically lower relapse rate compared with
recipients of autologous marrow, but OS, EFS, and NRM rates were not significantly different.
They described that the use of HLA-MSD marrow results in a lower relapse rate and, thus, for
some individuals, may be preferable to the use of autologous marrow. The European Group
for Blood and Marrow Transplantation (EBMT) directed a retrospective study of 45 patients
(median age, 29 years) with refractory or relapsed HL, who received matched sibling allogeneic
versus autoSCT [36]. The 4-year actuarial probabilities of OS, PFS, relapse, and NRM were
25%, 15%, 61%, and 48% and 37%, 24%, 61%, and 27% after alloBMT and autoBMT, respec‐
tively. The 4-year actuarial probability of survival was 30% after alloBMT and 64% after
autoBMT (P =.007). This difference is mainly due to a higher TRM rate after alloBMT (65% v
12%, P =.005). The authors suggested that patients with relapsed or resistant HL derive no
benefit from alloSCT over autoSCT. However, lower relapse rate (13%) among patients with
acute GVHD, supporting a substantial GVHL effect with alloSCT. The second EBMT registry
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reported by Peniket et al. in 2003, One-hundred-sixty-seven poor-prognosis HL patients who
underwent myeloablative transplantation (77% with stage III or IV at diagnosis and 42% with
chemoresistant disease) were assessed. [37] These patients received allogeneic transplants as
their first transplant procedure. Actuarial OS at 4 years from transplantation was 24.7% years.
These outcomes are relatively poor because of the high TRM associated with these procedures
in patients with HL (51.7% actuarial procedure-related mortality at 4 years). The authors
concluded that the high TRM was probably a reflection of the large percentage of patients with
resistant disease. Gajewski et al. reviewed IBMTR data on 100 consecutive patients with HL
who received HLA-match sibling BMT between 1982 and 1992. All patients had advanced
disease [38]. Eighty-nine of 100 patients were not in remission at the time of transplant. Fifty
had pretransplant Karnofsky scores less than 90% and 27 had active infection in the week
before transplant. The 3-year probability of relapse and the probability of OS were 65% and
15, respectively. They concluded that the role of HLA-identical sibling BMTs have a limited
therapeutic effect in advanced HL. Akpek et al. evaluated the long-term outcome after
allogeneic and autologous blood or marrow transplantation in patients with relapsed or
refractory HL [39]. They analyzed the outcome of 157 consecutive patients with relapsed or
refractory HL, who underwent BMT between 1985 and 1998. There was a trend for probability
of relapse in sensitive patients to be less after alloBMT at 34% (range, 8% to 59%) versus 51%
(range, 36% to 67%) for the auto patients (HR = 0.51, P =.17). There seems to be a clinical GVHL
effect associated with alloBMT. Allogeneic BMT for HL also seems to have a lower risk of
secondary AML/MDS than autoBMT. Thus, alloBMT warrants continued study in HL.
Actually, comparisons of MAC versus autologous transplantation are problematic, because
MAC regimens are favored in patients with extensive prior therapy or comorbidities. In
general, higher NRM has been associated with myeloablative regimens and a greater risk of
relapse associated with autologous approaches, leading to similar long-term outcomes for
patients treated with each approach. The poor outcomes for allogeneic stem cell transplanta‐
tion in HL reported by the IBMTR and the EBMT may result from the selection of patients with
unfavorable risk for these studies. At that point, however, high rate of the TRM with MAC in
Hodgkin lymphoma is considered is rarely pursued [ 40]. Because of the most of this studies
have been reported at least couple decade ago, the effect of myeloablative transplantation in
HL may reevaluate with the developed supportive treatment modalities and new drugs.
3.2. Reduced-intensity conditioning
Last decade has seen a radical change in the approach to alloSCT. Previously, MAC regimens
were thought to be necessary for preventing graft rejection, making marrow space, and
providing antitumor activity. Interest in exploring transplantation with RIC in relapsed or
refractory HL arise from evidence of GVHL effect in these studies comparing allogeneic with
autologous transplantation. In an attempt to decrease TRM, authors increasingly have been
using alloSCT with RIC to patients with HL. Reduced-intensity conditioning could be
sufficient to restore allogeneic engraftment, and allow graft versus host reactions could
eliminate host hematopoiesis and provide antitumor effects. This has allowed treatment to be
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considered in older patients, or patients with co-morbidities, including those with HL for
whom prior autoSCT failed.
The EBMT analyzed the first retrospective analysis comparing RIC-alloSCT (n=89) with MAC-
alloSCT (n=79) in patients with relapsed or refractory HL [41]. In the RIC group NRM was
significantly decreased, OS was better and there was a trend for better PFS. Results demon‐
strated nearly twice the relapse incidence in the RIC group (57% vs. 30%), but the 5-year OS
was significantly higher in the RIC group (28% vs. 22%, P=0.003). They also indicate that the
existence of a GVHL effect correlated to the development of GVHD and additional efforts to
reduce the high relaps rate seen in both groups of patients. The centers reported the outcomes
of 143 patients undergoing unrelated donor reduced-intensity and nonmyeloablative (RIC/
NST) SCT for relapsed and refractory HL between 1999 and 2004 reported to the CIBMTR [42].
They analyzed Patients were heavily pretreated, including autoSCT in 89%. With a median
follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% and 33%,
respectively. The probabilities of PFS and OS were 30% and 56% at 1 year and 20% and 37%
at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90
were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplanta‐
tion was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact
outcomes.
Peggs et al. undertook RIC-alloSCT in 49 patients with multiply relapsed HL, 44 (90%) of whom
had progression of disease after previous autoSCT, number of previous treatment courses was
five [range 3-8], and time from diagnosis 4.8 years [range 0.6-4.8]) [43]. Thirty-one patients had
HLA matched donors who were related and 18 had donors who were unrelated. All patients
engrafted. Eight of 49 (16%) had grade II-IV acute GVHD and seven (14%) had chronic GVHD
before DLIs. Sixteen (33%) patients had DLI from 3 months after transplantation for residual
disease or progression. Six (38%) of the 16 developed grade II-IV acute GVHD and five
developed chronic GVHD. Nine (56%) showed disease responses after infusion (eight com‐
plete, one partial). Non-relapse-related mortality was 16.3% at 730 days (7.2% for patients who
had related donors vs. 34.1% for those with unrelated donors, p=0.0206). Projected 4 year OS
and PFS was 55.7% and 39.0%, respectively (62.0% and 41.5% for related donors). In this
prospectively study, authors showed that the potential for durable responses in patients who
have previously had substantial treatment for HL. In another prospective study, Alvarez et al.
described the results of RIC-alloSCT in patients with advanced HL. Forty patients with
relapsed or refractory HL were homogeneously treated with an RIC protocol (fludarabine 150
mg/m(2) intravenously plus melphalan 140 mg/m(2) intravenously) and cyclosporin A and
methotrexate as GVHD prophylaxis [44]. Twenty patients (50%) were allografted in resistant
relapse, and 38 patients received hematopoietic cells from an HLA-match sibling. Five patients
(12%) died from early TRM (before day +100 after allo-RIC). One-year TRM was 25%. Acute
GVHD developed in 18 patients (45%). Chronic GVHD developed in 17 (45%) of the 31
evaluable patients. The response rate 3 months after the allo-RIC was 67% (21 [52%] CRs and
6 [15%] partial remissions). Eleven patients received DLIs for disease relapse. The response
rate after DLI was 54% (3 complete remissions and 3 partial remissions). Overall survival and
PFS were 48% +/- 10% and 32% +/- 10% at 2 years, respectively. They suggest that RIC-alloSCT
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is feasible in heavily pretreated HL patients and has an acceptable early TRM. Results are better
in patients allografted in sensitive disease. Both responses observed after the development of
GVHD and DLI may suggest a GVHL effect. Allogeneic RIC has to be considered an effective
therapeutic approach for patients who have had treatment failure with previous autoSCT.
Anderlini et al. reported that a total of 40 patients with relapsed/refractory HL underwent RIC-
alloSCT [45]. Disease status at alloSCT was refractory relapse (n=14) or sensitive relapse (n=26).
The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin
(n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one.
The two groups had similar prognostic factors. Day 100 and cumulative TRMs (18-month)
were 5 and 22%. Twenty-four patients (60%) are alive (14 in CR or CR-unconfirmed) with a
median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression
n=8). FM patients had better OS (73 vs. 39% at 18 months; P=0.03), and a trend towards better
PFS (37 vs 21% at 18 months; P=0.2). Reduced intensity alloSCT is feasible in relapsed/refractory
HL patients with a low TRM. This group updated the results comparing outcomes of 58
patients with HL underwent RIC-alloSCT from a MRD (n=25) or a MUD (n=33) [46]. Forty-
eight (83%) had undergone prior autoSCT. Disease status at transplant was refractory relapse
(n=28) or sensitive relapse (n=30). Cumulative day 100 and 2-year TRM rates were 7% and 15%,
respectively (day 100 transplant-related mortality MRD vs. MUD 8% vs. 6%, p=ns; 2-year MRD
vs. MUD 13% vs. 16%, p=ns). Projected 2-year overall and progression-free survival rates are
64% (49-76%) and 32% (20-45%), with 2-year disease progression/relapse at 55% (43-70%).
There was no statistically significant difference in OS, PFS, and disease progression/relapse
between MRD and MUD transplants. They also suggested that FM as a preparative regimen
for RIC-alloSCT in progression-free survival HL is associated with a significant reduction in
TRM, with comparable results in MRD and MUD allograft.
In a recent study, Sarina et al., using RIC as a salvage option, to evaluate the role of alloSCT
in patients HL relapsing after autoSCT [47]. In this retrospective study based on the commit‐
ment of attending physicians to perform a salvage alloSCT; thus, only HL patients having
human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185
patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical
sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did
not differ. Two-year PFS and OS were better in the donor group (39.3% vs 14.2%, and 66% vs
42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis,
having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete
remission showed a better PFS and OS. They concluded that, that: (1) HL patients relapsing
after an autoSCT have a survival advantage if they undergo RIC alloSCT; (2) CR achievement
before RIC alloSCT is very important and influences patients’ clinical outcome; and (3) NRM
after RIC alloSCT is rather low; therefore, this procedure can be considered a feasible option
in the clinical setting. Stephen et al. [48] investigated the role of RIC-alloSCT in the management
of patients with HL. To further define its role they conducted a retrospective analysis of 285
patients with HL who underwent a RIC-alloSCT in order to identify prognostic factors that
predict outcome. Eighty percent of patients had undergone a prior autoSCT and 25% had
refractory disease at transplant. Non-relapse mortality was associated with chemorefractory
disease, poor performance status, age >45 and transplantation before 2002. For patients with
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no risk factors the 3-year non-relapse mortality rate was 12.5% compared to 46.2% for patients
with 2 or more risk factors. The use of an unrelated donor had no adverse effect on the non-
relapse mortality. Acute GVHD grades II-IV developed in 30% and chronic GVHD in 42%. The
development of chronic GVHD was associated with a lower relapse rate. The disease progres‐
sion rate at one and five years was 41% and 58.7% respectively and was associated with
chemorefractory disease and extent of prior therapy. Donor lymphocyte infusions were
administered to 64 patients for active disease of whom 32% showed a clinical response. Eight
out of 18 patients receiving DLIs alone had clinical responses. Progression-free and OS were
both associated with performance status and disease status at transplant. Patients with neither
risk factor had a 3- year PFS and OS of 42% and 56% respectively compared to 8% and 25% for
patients with one or more risk factors. Relapse within six months of a prior autologous
transplant was associated with a higher relapse rate and a lower progression-free. They
recommend that for patients deemed to be at high risk of failing an autologous transplant a
RIC-alloSCT may represent a more effective therapy and prospective comparative studies in
this setting should be considered.
On the basis of current data, some authors recommend RIC-allo for HL only in the context
of prospective clinical trials because allo-SCT trials continue to report disappointing relapse
rates. However, if clinicians feel strongly about proceeding with this strategy, patients with
refractory disease should be excluded and opportunities to exploit the GVHL effect should
be used [20].
3.3. The role of functional imaging in response assessment before RIC allo-SCT
Dodero et al. investigated the prognostic value of PET scanning in 80 patients who had
chemosensitive disease (34 patients with HG-NHL and 46 patients with HL before undergoing
to RIC and followed by alloSCT [49]. Positron emission tomography was used to assess before
they underwent alloSCT: 42 patients had negative PET studies, and 38 patients had positive
PET studies. Patients underwent allograft from MSD (n = 41) or alternative donors (n = 39). At
the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year
cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%,
respectively. The cumulative incidence of disease recurrence was significantly lower in the
PET-negative patients (25% vs. 56%; P =.007), but there was no significant difference between
the patients with or without chronic GVHD (P =.400). The patients who had negative PET
studies before undergoing alloSCT also had significantly better outcomes in terms of 3-year
OS (76% vs. 33%; P =.001) and 3-year PFS (73% vs. 31%; P =.001). On multivariate analysis, OS
was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type
of donor (HR, 6.26 for haploidentical vs. MSD; HR, 1.94 for MUD vs. MSD)l. The current results
indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients
who are eligible for RIC allografting.
In summary, autoSCT and alloSCT may be curative therapy options for patients with relapse/
refractory HL. AutoSCT is a standard therapy in relapsing HL patients especially responding
to salvage therapy. However, there is no place of autoSCT even in high-risk patients with first
remission. If patients with refractory disease after first-line treatment respond second line
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standard-dose therapy, these patients can benefit from an autoSCT. BEAM regimen is used as
the standard high dose-conditioning regimen. Detectable disease with functional imaging
before autoSCT can be an indicator of poor prognosis. Patients with relaps or progressive
disease after autoSCT need either alloSCT or other investigative approaches. The review of the
literature of alloSCT in HL patients has showed that in the last decade an increasing interest
has been raised on this topic. The results that are now available allow the following consider‐
ations: (i) Although myeloablative allogeneic SCT has lower relaps rate still has been associated
high non relaps mortality; (ii) The effect of myeloablative transplantation in HL may reevaluate
with the developed supportive treatment modalities and future studies should be aimed at
integrating intensified therapies and/or new drugs into the treatment plan to pursue the best
response before allografting; (iii) RIC alloSCT is a feasible option in relapsed/refractory HL
patients even if they were heavily pretreated; (iv) 20–30% of the allografted patients can be
long-term survivors after RIC alloSCT; (v) Complete response is the most important predictor
of a favorable outcome; (vi) PET scanning appears to be an accurate tool for assessing prognosis
in patients who are eligible for RIC allografting; thus (vii) Since the relapse risk after RIC-
alloSCT is still high maintenance treatment or immunological methods should be explored in
prospective clinical trials.
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